Diamond Pharma Services is a leading technical services and regulatory affairs consulting group, providing expert support and advice to pharmaceutical and biotechnology companies. Through analysis, interpretation and distillation of data, Diamond Pharma Services helps obtain and maintain medicinal product licences across all stages of a product’s life cycle.
The company focuses on three core areas:
EXPERTISE
Our staff are experts in EU regulatory affairs, pharmacovigilance, compliance and quality. Diamond Pharma Services has two offices in the European Union as well as being well placed to execute opportunities in the UK as its emerging standalone regulatory system evolves.
To provide a global solution, we have a collaborative network of US providers to assist companies in the navigation between EU and US regulatory pathways.
Regulatory Affairs
Our regulatory affairs consultants provide a full range of regulatory services from strategy through to outsourced regulatory departments.
- Development stage regulatory affairs services
- Clinical trial applications
- Licensing
- Post market and lifecycle regulatory affairs support
Pharmacovigilance
Comprehensive outsourced pharmacovigilance services ensuring compliance throughout the product life cycle. A bespoke and scalable service to meet the needs of your company.
Pharmacovigilance
Compliance and Quality
Full service quality assurance and Qualified Person activities from product concept to market and beyond.
- Qualified Person and Responsible Person services
- Product life cycle management
- Audits and inspections
Case Study
ATMP (Cell and Gene Therapy) Regulatory Support
The team at Diamond Pharma Services has world class regulatory experience in assisting companies developing advanced therapy medicinal products (ATMPs). Support can be provided for both cell and gene therapy products for Europe and the US.
Case Study
Compliance And Quality Division
Diamond Pharma Services offers GMP and GDP compliance services from clinical development to commercial distribution of the products’ lifecycle.
Case Study
Development Support
The Regulatory Development Department at Diamond Pharma Services has extensive experience in assisting companies to navigate through clinical development.
Case Study
Outsourced Regulatory Department
Sometimes there is sound logic for a pharmaceutical company to outsource a significant part of their regulatory tasks to a stable and experienced team.
Case Study
2021: The strategic opportunities for global medicines innovators in the UK
We firmly believe the UK’s post-Brexit regulatory picture provides a wealth of strategic opportunities for medicines innovators to advance clinical programmes here from both a Global and European perspective. As we embark on a new era the MHRA, as a world-class regulator, will establish an even stronger influence in regulatory guidance for clinical development and the UK should always be an early strategic consideration.
Case Study
Conversation with...
Antony Appleyard, Technical Director Regulatory, talks about working with ATMPs
Case Study
Clinical Trial Application Service
The CTA team at Diamond Pharma Services is integrated into the Regulatory Development Department. The team has extensive experience in CTA activities for a wide range of product types.
MARCH 02, 2021
ProPharma Group Announces the Acquisition of Diamond Pharma Services
ProPharma Group, a portfolio company of Odyssey Investment Partners, announces the acquisition of Diamond Pharma Services. Diamond Pharma Services provides…
Read articleFEBRUARY 04, 2021
2021: The strategic opportunities for global medicines innovators in the UK
Our latest article showcasing the opportunities for global medicines innovators in the UK
Read articleResources
Conversation with...
Antony Appleyard, Technical Director Regulatory, talks about working with ATMPs
10 February 2021Case Studies
Summary With experience of over 50 clinical development programmes in ATMPs, we’re in conversation with Antony A…
02 February 2021Brexit
We firmly believe the UK’s post-Brexit regulatory picture provides a wealth of strategic opportunities for medicines i…
18 December 2020Brexit
As we look to 2021 we are in uncharted territory as the UK leaves both the EU and the EMA. The UK will continue to be…
VACANCIES